儿童间质性肺病中的肺纤维化:综合分析
该多中心回顾性观察队列研究基于土耳其儿童间质性肺病登记库截至2024年1月的数据,纳入404例chILD患儿(47.5%女性),由经验丰富的放射科医师审阅胸部CT判断肺纤维化表现。183例有纤维化表现、221例无纤维化表现;纤维化组年龄更高、体重z评分更低(P<.05),两组肺功能参数无差异(P>.05),但纤维化组DLco更低(P=.015)。弥漫性肺实质疾病(DPLD)A类疾病患者肺纤维化患病率高于B类(P=.014)。作者认为肺纤维化是chILD常见并发症,随年龄增长更明显,DLPD-A类疾病、DLco较低或年龄较大的儿童中可能更常见。
要点
- 404例chILD患儿中,胸部CT有肺纤维化表现者183例、无纤维化表现者221例,纤维化组年龄更高且体重z评分更低(P<.05)。
- 两组肺功能参数无差异(P>.05),但纤维化组DLco更低(P=.015)。
- DPLD-A类疾病患者肺纤维化患病率高于DPLD-B类(P=.014)。
- CT纤维化表现构成:网格状异常34.9%、囊性异常21%、牵拉性支气管扩张19.8%、结构扭曲14.4%、蜂窝状改变2.5%。
- 作者认为肺纤维化在chILD中常见且随年龄增长更明显,应早期识别,尤其DLPD-A类、DLco较低或年龄较大的患儿。
适用人群与场景
- 土耳其儿童间质性肺病登记库中截至2024年1月的chILD患儿,共404例(47.5%女性),来自25个中心,中位年龄137个月(IQR 24-376个月)。
研究设计与关键结果
- 多中心回顾性观察队列研究,纳入404例chILD患儿(来自25个中心,47.5%女性),中位年龄137个月(IQR 24-376个月),按胸部CT有无肺纤维化表现分为纤维化组(n=183)与无纤维化组(n=221)。
- 基线:中位体重z评分-1.02(IQR -8.8至6.88),中位身高z评分-0.59(IQR -7至6.45),中位FEV1 68%(IQR 16%-127%),中位DLco 66%(IQR 21%-132%)。
- CT肺纤维化表现:网格状异常34.9%、囊性异常21%、牵拉性支气管扩张19.8%、结构扭曲14.4%、蜂窝状改变2.5%。
- 纤维化组较无纤维化组年龄更高、体重z评分更低(P<.05);两组肺功能参数无差异(P>.05),但纤维化组DLco更低(P=.015)。
- DPLD-A类疾病患者肺纤维化患病率高于DPLD-B类(P=.014)。
证据类型、等级与局限
- 证据类型:多中心回顾性观察队列研究(土耳其儿童间质性肺病登记库)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为肺纤维化是chILD常见并发症且随年龄增长更明显,强调早期识别的重要性。
- 作者认为有表面活性物质功能障碍或肺泡发育异常的儿童(DPLD-A类)发生肺纤维化的风险可能增加。
- 作者认为肺纤维化在DLco较低、DPLD-A类疾病或年龄较大的chILD患儿中可能更常见。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Childhood interstitial lung diseases (chILDs) encompass a wide range of rare, chronic respiratory disorders, with pulmonary fibrosis (PF) being the clinical entity closely associated with mortality and morbidity.
RESEARCH QUESTION: What is the prevalence and radiologic spectrum of PF in children with chILD, and how is it associated with pulmonary function and clinical characteristics?
STUDY DESIGN AND METHODS: This multicenter, retrospective observational cohort study used data from the Turkish Childhood Interstitial Lung Disease Registry as of January 2024. An experienced radiologist reviewed the chest CT scans for PF findings. Patients were divided into 2 groups based on the presence or absence of PF findings, and their clinical and demographic data were analyzed.
RESULTS: A total of 404 patients (47.5% female) from 25 centers were included. The median age was 137 months (interquartile range [IQR], 24-376 months). The median z score for weight was -1.02 (IQR, -8.8 to 6.88), and the median z score for height was -0.59 (IQR, -7 to 6.45). The median FEV1 was 68% (IQR, 16%-127%), and the median diffusion capacity of the lungs for carbon monoxide (Dlco) was 66% (IQR, 21%-132%). The PF findings were as follows: reticular abnormalities, 34.9% of patients; cystic abnormalities, 21% of patients; traction bronchiectasis, 19.8% of patients; architectural distortion, 14.4% of patients; and honeycombing, 2.5% of patients. Two groups were compared based on the presence (n = 183) or absence (n = 221) of PF findings; the group with fibrotic findings showed a higher age and lower z score for weight (P < .05). Although no differences were found in PFT parameters between groups (P > .05), Dlco was lower in the fibrotic group (P = .015). The prevalence of PF was higher in patients with diffuse parenchymal lung disease (DPLD) group A disorders than in those with DPLD group B (P = .014).
INTERPRETATION: Our results show that PF is a common complication in chILD and becomes more pronounced with age, underscoring the importance of early detection. The higher rate of PF findings in patients with DPLD-A disorders suggests that children with surfactant dysfunction or alveolar developmental abnormalities may be at an increased risk of PF developing. PF may be more common in children with a lower Dlco score, with a DPLD-A disorder, or of an older age.
参考来源
- Kekec H, Aslan AT, Akdulum I, et al. Understanding Pulmonary Fibrosis in Pediatric Interstitial Lung Disease: A Comprehensive Analysis. Chest. 2026. PMID: 41740922. doi:10.1016/j.chest.2026.01.022
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。